

Francesca Palandri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1613419/publications.pdf>

Version: 2024-02-01

179
papers

5,674
citations

93792

39
h-index

107981

68
g-index

182
all docs

182
docs citations

182
times ranked

5313
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). <i>Leukemia and Lymphoma</i> , 2022, 63, 189-198.	0.6	3
2	Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 939-949.	2.3	6
3	Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2693-2705.	1.2	6
4	Second versus first wave of COVID-19 in patients with MPN. <i>Leukemia</i> , 2022, 36, 897-900.	3.3	7
5	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study. <i>British Journal of Haematology</i> , 2022, 197, 190-200.	1.2	7
6	Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. <i>Annals of Hematology</i> , 2022, 101, 963-978.	0.8	16
7	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. <i>Cancer</i> , 2022, 128, 2449-2454.	2.0	7
8	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. <i>Lancet Haematology</i> , 2022, 9, e301-e311.	2.2	46
9	Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis. <i>Cancers</i> , 2022, 14, 1799.	1.7	0
10	Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity. <i>Leukemia Research</i> , 2022, 116, 106819.	0.4	5
11	Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. <i>Lancet Haematology</i> , 2022, 9, e480-e492.	2.2	18
12	Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. <i>Current Oncology</i> , 2022, 29, 4970-4980.	0.9	2
13	Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series. <i>Hematological Oncology</i> , 2021, 39, 123-128.	0.8	1
14	Is there a gender effect in polycythemia vera?. <i>Annals of Hematology</i> , 2021, 100, 11-25.	0.8	9
15	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	1.2	19
16	Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients' satisfaction. <i>British Journal of Haematology</i> , 2021, 192, e48-e51.	1.2	14
17	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. <i>Leukemia</i> , 2021, 35, 485-493.	3.3	70
18	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	2.8	41

#	ARTICLE	IF	CITATIONS
19	Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 49.	3.5	11
20	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 21.	2.8	26
21	Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. <i>British Journal of Haematology</i> , 2021, 193, 386-396.	1.2	23
22	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021, 39, 409-418.	0.8	9
23	The "Vesicular Intelligence" Strategy of Blood Cancers. <i>Genes</i> , 2021, 12, 416.	1.0	7
24	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	2.0	14
25	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. <i>Blood</i> , 2021, 138, 571-583.	0.6	26
26	Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. <i>Leukemia</i> , 2021, 35, 3455-3465.	3.3	25
27	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. <i>Leukemia</i> , 2021, 35, 2989-2993.	3.3	34
28	The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report. <i>Hematology Reports</i> , 2021, 13, 8814.	0.3	0
29	Long-term follow-up of recovered MPN patients with COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 115.	2.8	9
30	Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 2881-2892.	0.8	59
31	The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters. <i>Cells</i> , 2021, 10, 2316.	1.8	8
32	Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. <i>Cancers</i> , 2021, 13, 4750.	1.7	8
33	Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110483.	1.1	7
34	A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera. <i>Cancers</i> , 2021, 13, 4968.	1.7	0
35	Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants. <i>Cancers</i> , 2021, 13, 5531.	1.7	3
36	An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera. <i>Frontiers in Oncology</i> , 2021, 11, 715217.	1.3	7

#	ARTICLE	IF	CITATIONS
37	Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12606.	1.0	1
38	The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. <i>Bone Marrow Transplantation</i> , 2020, 55, 708-716.	1.3	23
39	Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , 2020, 95, E1-E3.	2.0	8
40	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	2.0	106
41	Second cancers in MPN: Survival analysis from an international study. <i>American Journal of Hematology</i> , 2020, 95, 295-301.	2.0	34
42	Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. <i>Thrombosis Research</i> , 2020, 185, 88-95.	0.8	7
43	How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy: a GIMEMA MPN WP survey. <i>Leukemia</i> , 2020, 34, 2805-2808.	3.3	16
44	The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis. <i>Oncotarget</i> , 2020, 9, 1782575.	2.1	20
45	Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. <i>Nature</i> , 2020, 588, 157-163.	13.7	90
46	COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. <i>Leukemia</i> , 2020, 34, 2813-2814.	3.3	16
47	Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study. <i>Leukemia</i> , 2020, 34, 1949-1953.	3.3	13
48	Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3399.	1.8	4
49	Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-world practice. <i>Annals of Hematology</i> , 2020, 99, 65-72.	0.8	13
50	Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. <i>British Journal of Haematology</i> , 2020, 189, 888-903.	1.2	61
51	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	0.8	15
52	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020, 135, 381-386.	0.6	18
53	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. <i>Blood</i> , 2020, 136, 171-182.	0.6	65
54	Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach. <i>Hematological Oncology</i> , 2019, 37, 424-433.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 1933-1936.	0.8	5
56	Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. <i>American Journal of Hematology</i> , 2019, 94, E239-E242.	2.0	3
57	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. <i>Leukemia</i> , 2019, 33, 1996-2005.	3.3	67
58	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	0.8	3
59	Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. <i>Frontiers in Oncology</i> , 2019, 9, 1186.	1.3	142
60	Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2019, 185, 987-991.	1.2	16
61	Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients. <i>British Journal of Haematology</i> , 2019, 184, 424-430.	1.2	16
62	Treating early-stage myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 241-253.	0.8	5
63	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	0.8	10
64	Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. <i>Annals of Hematology</i> , 2018, 97, 745-754.	0.8	11
65	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian “Back to Life”™ project. <i>Quality of Life Research</i> , 2018, 27, 1545-1554.	1.5	9
66	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	0.8	46
67	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. <i>Haematologica</i> , 2018, 103, e392-e394.	1.7	31
68	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 25.	2.8	26
69	Comparison of <i>JAK2</i> ^{V617F} -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. <i>Hematological Oncology</i> , 2018, 36, 269-275.	0.8	11
70	Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	0.8	29
71	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. <i>Blood Cancer Journal</i> , 2018, 8, 89.	2.8	13
72	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.4	23

#	ARTICLE	IF	CITATIONS
73	Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. <i>Annals of Hematology</i> , 2018, 97, 1591-1600.	0.8	53
74	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	1.2	7
75	Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34+Cells. <i>Mediators of Inflammation</i> , 2018, 2018, 1-14.	1.4	3
76	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	1.8	24
77	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. <i>Blood Cancer Journal</i> , 2018, 8, 49.	2.8	30
78	Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study). <i>Blood</i> , 2018, 132, 1135-1135.	0.6	3
79	Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI). <i>Blood</i> , 2018, 132, 4312-4312.	0.6	0
80	The Malignant Hemopoietic Clone of Triple Negative Patients with Myelofibrosis Shows in Vitro Functional Defects but Is Highly Responsive to the Pro-Survival Signals of Circulating Autologous Microvesicles. <i>Blood</i> , 2018, 132, 4334-4334.	0.6	0
81	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. <i>Blood</i> , 2018, 132, 4303-4303.	0.6	3
82	Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. <i>European Journal of Haematology</i> , 2017, 98, 371-377.	1.1	71
83	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. <i>Lancet Oncology</i> , The, 2017, 18, 88-99.	5.1	205
84	Mutations in <i>JAK2</i> and <i>Calreticulin</i> genes are associated with specific alterations of the immune system in myelofibrosis. <i>Oncolimmunology</i> , 2017, 6, e1345402.	2.1	33
85	New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment. <i>Hematological Oncology</i> , 2017, 35, 145-150.	0.8	2
86	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017, 92, 37-41.	2.0	62
87	The relevance of a low <i>JAK2</i> V617F allele burden in clinical practice: a monocentric study. <i>Oncotarget</i> , 2017, 8, 37239-37249.	0.8	18
88	Assessment of the interlaboratory variability and robustness of <i>JAK2</i> V617F mutation assays: A study involving a consortium of 19 Italian laboratories. <i>Oncotarget</i> , 2017, 8, 32608-32617.	0.8	5
89	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086.	0.8	63
90	Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly. <i>Mediators of Inflammation</i> , 2016, 2016, 1-7.	1.4	23

#	ARTICLE	IF	CITATIONS
91	Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. <i>American Journal of Hematology</i> , 2016, 91, E267-72.	2.0	68
92	Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity. <i>American Journal of Hematology</i> , 2016, 91, E329-30.	2.0	6
93	Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. <i>British Journal of Haematology</i> , 2016, 174, 160-162.	1.2	7
94	Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. <i>American Journal of Hematology</i> , 2016, 91, 318-321.	2.0	28
95	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. <i>Blood</i> , 2016, 128, 1128-1128.	0.6	4
96	Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233). <i>Blood</i> , 2016, 128, 3107-3107.	0.6	3
97	Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. <i>Blood</i> , 2016, 128, 4251-4251.	0.6	2
98	Crucial factors of the inflammatory microenvironment (IL-1 ² /TNF- ¹ /TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an <i>in vitro</i> study. <i>Oncotarget</i> , 2016, 7, 43974-43988.	0.8	21
99	MYH-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature. <i>British Journal of Haematology</i> , 2015, 170, 729-731.	1.2	11
100	Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2687.	2.0	4
101	Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. <i>Annals of Hematology</i> , 2015, 94, 519-520.	0.8	29
102	Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis. <i>Annals of Hematology</i> , 2015, 94, 339-341.	0.8	7
103	Circulating CD4 ⁺ CD25 ⁺ Foxp3 ⁺ cells are increased in patients with immune thrombocytopenia. <i>Immunology Letters</i> , 2015, 166, 63-64.	1.1	4
104	Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2014, 7, 397-406.	1.0	10
105	TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014005.	0.5	32
106	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. <i>British Journal of Haematology</i> , 2014, 167, 541-546.	1.2	47
107	The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study. <i>American Journal of Hematology</i> , 2014, 89, 1047-1050.	2.0	26
108	Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. <i>Annals of Hematology</i> , 2013, 92, 67-78.	0.8	43

#	ARTICLE	IF	CITATIONS
109	Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. <i>Blood</i> , 2013, 122, 1634-1648.	0.6	152
110	Update on the treatment of Ph-negative myeloproliferative neoplasms. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 251-262.	0.7	1
111	Absence of bidirectional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of <i>MPL</i> polymorphisms. <i>British Journal of Haematology</i> , 2013, 161, 142-144.	1.2	17
112	Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. <i>Haematologica</i> , 2013, 98, 875-880.	1.7	97
113	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. <i>Blood</i> , 2013, 122, 258-258.	0.6	2
114	Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy. <i>Blood</i> , 2013, 122, 380-380.	0.6	2
115	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. <i>Blood</i> , 2013, 122, 1486-1486.	0.6	0
116	4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. <i>Blood</i> , 2013, 122, 4000-4000.	0.6	0
117	Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain. <i>Blood</i> , 2013, 122, 3986-3986.	0.6	0
118	Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. <i>Cancer Treatment Reviews</i> , 2012, 38, 241-248.	3.4	29
119	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012, 120, 761-767.	0.6	110
120	Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency. <i>Hematology Reports</i> , 2012, 4, e10.	0.3	3
121	Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients. <i>British Journal of Haematology</i> , 2012, 156, 281-284.	1.2	29
122	Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years. <i>British Journal of Haematology</i> , 2012, 156, 676-679.	1.2	7
123	Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 159-170.	2.0	20
124	Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications. <i>Blood</i> , 2012, 120, 692-692.	0.6	2
125	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011, 117, 5591-5599.	0.6	97
126	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2011, 117, 6793-6800.	0.6	98

#	ARTICLE	IF	CITATIONS
127	Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. <i>Leukemia Research</i> , 2011, 35, 1527-1529.	0.4	6
128	The CD47 pathway is deregulated in human immune thrombocytopenia. <i>Experimental Hematology</i> , 2011, 39, 486-494.	0.2	21
129	Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. <i>Annals of Hematology</i> , 2011, 90, 933-938.	0.8	61
130	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. <i>Blood</i> , 2011, 118, 453-453.	0.6	1
131	Imatinib in chronic myeloid leukemia elderly patients. <i>Aging</i> , 2011, 3, 1125-1126.	1.4	5
132	Decreased Expression of Indoleamine 2,3-Dioxygenase 1 in Dendritic Cells From Patients with Immune Thrombocytopenia Induces Impaired Regulatory T-Cell Development. <i>Blood</i> , 2011, 118, 696-696.	0.6	0
133	Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies. <i>Blood</i> , 2011, 118, 112-112.	0.6	6
134	Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients. <i>Blood</i> , 2011, 118, 3775-3775.	0.6	0
135	The response to imatinib and interferon- α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. <i>Haematologica</i> , 2010, 95, 1415-1419.	1.7	43
136	Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a head-to-head comparison TM . <i>Leukemia and Lymphoma</i> , 2010, 51, 583-591.	0.6	25
137	Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. <i>Leukemia Research</i> , 2010, 34, 143-147.	0.4	37
138	Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. <i>Haematologica</i> , 2010, 95, 1038-1040.	1.7	19
139	Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 2748-2754.	0.8	56
140	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , 2010, 116, 359-359.	0.6	14
141	Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression. <i>Blood</i> , 2010, 116, 885-885.	0.6	5
142	Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy. <i>Blood</i> , 2010, 116, 1666-1666.	0.6	0
143	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. <i>Blood</i> , 2010, 116, 2281-2281.	0.6	0
144	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis. <i>Blood</i> , 2010, 116, 1230-1230.	0.6	2

#	ARTICLE	IF	CITATIONS
145	Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMoR) at 12 Months. <i>Blood</i> , 2010, 116, 668-668.	0.6	0
146	Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response. <i>Clinical Cancer Research</i> , 2009, 15, 1059-1063.	3.2	28
147	Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. <i>Leukemia Research</i> , 2009, 33, e218-e220.	0.4	9
148	Response definitions and European Leukemianet Management recommendations. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 331-341.	0.7	60
149	Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience. <i>Leukemia and Lymphoma</i> , 2009, 50, 481-484.	0.6	14
150	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , 2009, 50, 114-118.	0.6	9
151	JAK2 ^{V617F} mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. <i>Leukemia and Lymphoma</i> , 2009, 50, 247-253.	0.6	32
152	Long-term follow-up of 386 consecutive patients with essential thrombocythemia: Safety of cytoreductive therapy. <i>American Journal of Hematology</i> , 2009, 84, 215-220.	2.0	70
153	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , 2009, 94, 205-212.	1.7	73
154	Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. <i>Haematologica</i> , 2009, 94, 1758-1761.	1.7	35
155	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009, 113, 3428-3434.	0.6	59
156	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. <i>Blood</i> , 2009, 113, 4497-4504.	0.6	173
157	Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. <i>Blood</i> , 2009, 114, 2168-2171.	0.6	160
158	Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. <i>Blood</i> , 2009, 114, 4933-4938.	0.6	203
159	High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.. <i>Blood</i> , 2009, 114, 2176-2176.	0.6	1
160	The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. <i>Blood</i> , 2009, 114, 2192-2192.	0.6	3
161	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. <i>Blood</i> , 2009, 114, 2205-2205.	0.6	8
162	CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.. <i>Blood</i> , 2009, 114, 2174-2174.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2008, 83, 520-520.	2.0	2
164	Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <i>Haematologica</i> , 2008, 93, 1792-1796.	1.7	91
165	Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008, 26, 106-111.	0.8	48
166	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- α : 5-year outcome. <i>Haematologica</i> , 2008, 93, 770-774.	1.7	53
167	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , 2008, 112, 181-181.	0.6	19
168	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. <i>Blood</i> , 2008, 112, 185-185.	0.6	13
169	Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score. <i>Blood</i> , 2008, 112, 3190-3190.	0.6	4
170	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. <i>Haematologica</i> , 2007, 92, 401-404.	1.7	172
171	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. <i>Haematologica</i> , 2007, 92, 101-105.	1.7	57
172	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. <i>Blood</i> , 2007, 110, 3540-3546.	0.6	688
173	Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase. <i>Haematologica</i> , 2007, 92, 1579-1580.	1.7	10
174	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. <i>Blood</i> , 2007, 110, 26-26.	0.6	4
175	Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome-Positive Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, e51-e52.	0.8	61
176	Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).. <i>Blood</i> , 2006, 108, 836-836.	0.6	17
177	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. <i>Blood</i> , 2006, 108, 4805-4805.	0.6	0
178	Management of acute graft versus host disease (GvHD). <i>The Hematology Journal</i> , 2004, 5, 189-196.	2.0	38
179	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.. <i>Blood</i> , 2004, 104, 4655-4655.	0.6	0